Información:
Error:
ID
33350
Descripción
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00796107
Link
https://clinicaltrials.gov/show/NCT00796107
Palabras clave
Versiones (1)
- 6/12/18 6/12/18 -
Titular de derechos de autor
See clinicaltrials.gov
Subido en
6 de diciembre de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Breast Cancer NCT00796107
Eligibility Breast Cancer NCT00796107
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00796107
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Postmenopausal state
Item
postmenopausal female patients;
boolean
C0232970 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Locally advanced breast cancer
Item
stage iv or locally advanced breast cancer;
boolean
C0346993 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C3495949 (UMLS CUI [2])
Measurable Disease
Item
measurable disease;
boolean
C1513041 (UMLS CUI [1])
Letrozole failed
Item
letrozole failure (part 2);
boolean
C0246421 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status <=2.
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Secondary malignant neoplasm of female breast
Item
previous chemotherapy for metastatic breast cancer;
boolean
C1514457 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,2])
Antibody therapy Advanced disease | Immunotherapy Advanced disease
Item
concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug;
boolean
C0281176 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0679246 (UMLS CUI [2,2])
C0679246 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0679246 (UMLS CUI [2,2])
Primary tumor | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix
Item
history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix;
boolean
C0677930 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
Therapeutic radiology procedure
Item
concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.
boolean
C1522449 (UMLS CUI [1])